Ranbaxy to market BioPro's Gliadel Wafer in India
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratorieshas signed an exclusive licensing agreement with BioPro Pharmaceutical of the US to promote and market Gliadel Wafer (polifeprosan 20 with carmustine implant) in India. The US FDA-approved product is used for the treatment of newly diagnosed high-grade malignant gliomas and recurrent glioblastoma multiforme. Ranbaxy has received import permission for Gliadel Wafer in India. The product is manufactured by MGI Pharma and BioPro retains the marketing rights in some Asian territories including China, Hong Kong, Taiwan, Korea, Singapore, Indonesia, the Philippines, Malaysia, Thailand and India. Gliadel is approved in several countries including many in Europe, Australia, Canada, South Africa, Israel and Korea. Unofficial estimates peg the prevalence of CNS tumours in India at two to five new cases per 100,000 per year.
You may also be interested in...
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
India IPR Wheels Are Turning: Novartis, Bayer, Sun, Legal Heads Discuss Realities
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.